Trials and tribulations

27 July 2017 By John Foley

A cancer treatment failed to live up to high hopes, wiping as much as $14 billion off the company’s value. The outlook for the UK drugmaker and its boss Pascal Soriot is suddenly more uncertain. But there are other areas of growth – and Astra is now an easier takeover target.

This content is for Subscribers only

To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)